Growth on track but sequentially soft; betting on H2 capacity inflection

Revenue grew 11.7% YoY (₹554.3 Cr vs ₹496 Cr). QoQ declined -7.9%.

YoY growth okay (11.7%), but PAT down 29.7% QoQ; OPM 26.7% below target 28–30%.

Discovery capacity in Q1 already sold out; Bidar blocks on track for H2/Q3. Claim credible.

CRO ₹~222 Cr at 26% growth. CDMO ₹~332 Cr at 6% growth — weak.

Cited in call; no contradicting data. Reflects relationship depth.

Discovery capacity Q1 expected to take 1.5 years to fill; now sold out. Early-stage deployment faster than modeled.

6 late-phase molecules added in 15 months (5 from large pharma FTE). One customer now end-to-end (discovery to commercial). Prior call said 'early stage'; now showing concrete progression.

CDMO +6% YoY in Q1. Prior year FY26 showed stronger momentum. Lumpy but concerning on absolute growth.

28–30% EBITDA target maintained, but Q1 OPM 26.7% below range. No rerate of near-term margin assumptions.

Krishna said still 'early stages,' 'gradual increase' expected. Wuxi model took years. India CDMO is first phase (discovery + tech transfer); middle phase (FTE) now migrating. Long way to go in scale.

Krishna said 'integrated platform helped' and 'not one customer, multiple converted.' Won't quantify per-customer revenue.

Siva said 'decently sized' (three products), 'lower volume' (one). Primary in two of three. Vague on absolute value per product.

Krishna explained: clinical-only up to Phase 2, not commercial. Driven by customer need for China+1 early clinical supply. Only works with existing development relationships.

Krishna said 'primary intent of every pharma is to leave with us for commercial,' but capacity mismatches possible. Didn't give explicit retention %. Claimed advantages (19 of 25 pharma, preferred vendor status).

Siva: internal hurdle rates higher than company ROCE/ROE. Stress-tested vs historical. Capability-building capex hard to defer; capacity-addition capex can modulate. Showed discipline by slowing before when demand slowed.

Siva: 'Largely on schedule, 1–2 months variance.' Discovery capacity Q1 on stream and sold out. Bidar blocks on track for H2/Q3.

Siva: HTE is multiple scenarios/data points; AI initiative is different—eliminate non-value-add tasks (document generation, literature synthesis). Will update before end of year.

Krishna: Yes, all three. Not just GLP-1; building broad platform (PDCs, macrocyclic, radiochemistry). Clinical capacity sooner, commercial 2028.

Siva: Guidance is over 3–5-year horizon; business is lumpy. Quarter timing drives Q-o-Q volatility. FY26 was exceptional (30%), long-term midpoint is 15–20%. Won't put 'all bets' on higher target—discipline matters.

Siva: 3-way funnel: (1) biotech acquired by pharma Sai works with = stays; (2) pharma's own FTE projects progress to Sai; (3) pharma acquires biotech Sai doesn't know, product transferred due to Sai's preferred vendor status. Pharma relationship is key.

Krishna: Majority work early-stage discovery, multiple customers (large pharma + biotech). One dedicated development lab online. GMP pilot facility coming online (clinical + discovery support). 2028 is true commercial capacity. On chain length: development teams do longer chains (8–12 AA); commercial starts with smaller mature pipelines but seeing demand for longer chains.

Krishna: Pilot scale already building. More plans TBD. Significant footprint spans discovery and development for all ADCs.

Reaffirmed this call. Supported by FTE funnel expansion, late-phase molecule growth (6 in 15 months), and big pharma relationship deepening. But near-term lumpiness acknowledged.

Maintained but not evidenced: Q1 OPM 26.7% below range. Capex cycle (₹1,100–1,300 Cr) will depress near-term depreciation. Margins expected to recover post-2028 when capacity is fully utilized.

Reaffirmed; on track. Bidar blocks, discovery lab, peptide facility, formulation—aligned with guidance. One-time heavy investment cycle.

CDMO +6% YoY in Q1 vs CRO +26%. CDMO is 60% of revenue. Weak growth in core business segment suggests capacity/pricing/mix headwinds.

Q1 PAT down 29.7% QoQ despite 11.7% YoY growth. Business is inherently lumpy but near-term predictability is low. Investors may discount guidance.

Q1 OPM 26.7% vs 28–30% target. ₹1,100–1,300 Cr capex cycle will increase depreciation; margins may remain suppressed into FY28. Guidance assumes margin recovery but timing uncertain.

Peptide, ADC, formulation capabilities still immature (<5% of revenue). Peptide manufacturing not online until 2028. Formulation 6 months away. Ramp timelines and customer adoption uncertain.

While 19 of 25 top pharma are customers (diversified), FTE model creates deeper single-customer dependencies. If one large pharma reduces engagement or acquires a competing CDMO, revenue impact is high.